Global Drugs for Schistosomiasis Market Growth 2023-2029

Global Drugs for Schistosomiasis Market Growth 2023-2029

Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.
LPI (LP Information)' newest research report, the “Drugs for Schistosomiasis Industry Forecast” looks at past sales and reviews total world Drugs for Schistosomiasis sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Schistosomiasis sales for 2023 through 2029. With Drugs for Schistosomiasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Schistosomiasis industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Schistosomiasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Schistosomiasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Drugs for Schistosomiasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Schistosomiasis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Schistosomiasis.
The global Drugs for Schistosomiasis market size is projected to grow from US$ 80 million in 2022 to US$ 105.1 million in 2029; it is expected to grow at a CAGR of 105.1 from 2023 to 2029.
Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.
East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,
Followed by West Africa(20%).
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Schistosomiasis market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Praziquantel
Oxamniquine
Other
Segmentation by application
S. haematobium
S. mansoni
S. japonicum
S. mekongi
S. intercalatum
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Shin Poong
Merck
Bayer
EIPICO
Chandra Bhagat Pharma
Taj Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Drugs for Schistosomiasis market?
What factors are driving Drugs for Schistosomiasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drugs for Schistosomiasis market opportunities vary by end market size?
How does Drugs for Schistosomiasis break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.